Director/PDMR Shareholding

RNS Number : 0486D

GlaxoSmithKline PLC

01 July 2016

 

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with Disclosure and Transparency Rule 3.1.4R(1)(a), I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc (the 'Company').

On 30 June 2016, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £15.59 per Ordinary Share, and notional ADSs at a price of $42.37 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2016 to 30 June 2016:

Non Executive Director	Ordinary Shares	No. of ADSs
Sir Philip Hampton	2,806.286
Professor Sir Roy Anderson	581.302
Vindi Banga	2,140.172
Stacey Cartwright	461.033
Lynn  Elsenhans		845.582
Judy Lewent		436.213
Urs Rohner	541.212

Jesse Goodman was appointed to the Board with effect from 1 January 2016. In accordance with the share allocation arrangements for Non-Executive Directors, 25% of Jesse Goodman's fees will be retained and will be reinvested in the Company's ADSs at a future date, to be mutually agreed.

The Company and the Non-Executive Directors were advised of these allocations on 1 July 2016.

V A Whyte

Company Secretary

1 July 2016

 

END

 

 

DSHEFLFBQDFLBBZ